Literature DB >> 21826737

The prevalence and clinical-demographic correlates of diabetes mellitus in chronic schizophrenic patients receiving clozapine.

Ruiling Zhang1, Wei Hao, Miao Pan, Chuansheng Wang, Xiuli Zhang, Da Chun Chen, Mei Hong Xiu, Fu De Yang, Thomas R Kosten, Xiang Yang Zhang.   

Abstract

OBJECTIVE: To examine the prevalence and correlates of diabetes in a large sample of Chinese patients with schizophrenia on long-term clozapine treatment, because this population previously has received little systematic study.
METHODS: Two hundred and six inpatients meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition schizophrenia criteria were recruited in a cross-sectional naturalistic study, and compared with 615 healthy control subjects matched for age, sex, education, and body mass index (BMI). The patient's psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Diagnoses of diabetes were established through review of medical records and fasting blood glucose testing, or an oral glucose tolerance test.
RESULTS: Diabetes mellitus was more common in patients than in the normal controls (22.3% vs 6.2%) (odds ratio = 4.37, confidence interval (CI) 2.76-6.92, p < 0.001). The prevalence of diabetes increased with age across five age-groups as compared with normal controls (X(2) = 18.0, df = 4, p = 0.001). The PANSS total score and sub-scores showed no differences between the diabetic and non-diabetic groups. Logistic regression in the patients revealed significant associations between diabetes and a family history of diabetes (p < 0.001), age (p < 0.01), and BMI (p < 0.05).
CONCLUSION: Long-term clozapine treatment was associated with an increased and clinically important risk of diabetes mellitus in Chinese chronic schizophrenic patients, which is consistent with previous reports in Western populations.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826737     DOI: 10.1002/hup.1220

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  5 in total

1.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

2.  Undiagnosed Diabetes Mellitus and Associated Factors among Psychiatric Patients Receiving Antipsychotic Drugs at The University of Gondar Hospital, Northwest Ethiopia.

Authors:  Daniel Asmelash; Wondale Getnet; Belete Biadgo; Sintayehu Ambachew; Tadele Melak; Lemmesa Melese; Shiwaneh Damite; Habtamu Wondifraw Baynes; Molla Abebe
Journal:  Ethiop J Health Sci       Date:  2018-01

3.  The magnitude of undiagnosed diabetes and Hypertension among adult psychiatric patients receiving antipsychotic treatment.

Authors:  Agete Tadewos Hirigo; Tesfaye Teshome
Journal:  Diabetol Metab Syndr       Date:  2020-09-07       Impact factor: 3.320

4.  The prevalence and clinical characteristics of diabetes mellitus in Chinese inpatients with chronic schizophrenia: a multicenter cross-sectional study.

Authors:  Yanni Wang; Lingyun Zeng; Lijuan Chen; Xin Zhou; Lijuan Huo; Tingwei Wang; Yongjie Zhou; Xiangyang Zhang
Journal:  PeerJ       Date:  2021-11-30       Impact factor: 2.984

5.  Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.

Authors:  Krithika Rajagopalan; David Trueman; Lydia Crowe; Daniel Squirrell; Antony Loebel
Journal:  Pharmacoeconomics       Date:  2016-07       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.